Pfizer Buys Anacor With Blockbuster Ambitions For Crisaborole
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer agreed to acquire Anacor for roughly $5.2bn, with the expectation that its late-stage PDE4 inhibitor crisaborole, under review by FDA for the treatment of atopic dermatitis, will generate peak sales of more than $2bn.